Group One Trading’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-15,630
| Closed | -$88.6K | – | 9046 |
|
|
2025
Q3 | $88.6K | Sell |
15,630
-5,332
| -25% | -$27.3K | ﹤0.01% | 5456 |
|
|
2025
Q2 | $79.9K | Sell |
20,962
-54,512
| -72% | -$169K | ﹤0.01% | 5174 |
|
|
2025
Q1 | $198K | Sell |
75,474
-1,634
| -2% | -$5.32K | ﹤0.01% | 4019 |
|
|
2024
Q4 | $273K | Buy |
77,108
+13,400
| +21% | +$51.3K | ﹤0.01% | 3678 |
|
|
2024
Q3 | $291K | Buy |
+63,708
| New | +$308K | ﹤0.01% | 3291 |
|
|
2024
Q1 | – | Sell |
-411
| Closed | -$2.3K | – | 7864 |
|
|
2023
Q4 | $2.58K | Sell |
411
-1,700
| -81% | -$9.73K | ﹤0.01% | 6749 |
|
|
2023
Q3 | $15K | Sell |
2,111
-7,800
| -79% | -$61.5K | ﹤0.01% | 6098 |
|
|
2023
Q2 | $101K | Buy |
+9,911
| New | +$103K | ﹤0.01% | 4609 |
|
|
2023
Q1 | – | Sell |
-1,444
| Closed | -$10.6K | – | 7871 |
|
|
2022
Q4 | $10.4K | Sell |
1,444
-25,616
| -95% | -$157K | ﹤0.01% | 6015 |
|
|
2022
Q3 | $176K | Buy |
27,060
+25,738
| +1,947% | +$138K | ﹤0.01% | 4271 |
|
|
2022
Q2 | $6K | Buy |
1,322
+668
| +102% | +$3.31K | ﹤0.01% | 7029 |
|
|
2022
Q1 | $4K | Buy |
+654
| New | +$3.21K | ﹤0.01% | 7559 |
|
Group One Trading's SCPH Position: Q4 2025 in Review
Group One Trading sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 15,630 shares — an estimated $88.6K sold.
Group One Trading first reported a position in SCPH in Q1 2022 and held it in 12 quarters. The position peaked at $291K in Q3 2024. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Group One Trading reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 15,630 scPharmaceuticals shares in Q4 2025, an estimated $88.6K.
- Group One Trading first reported a position in scPharmaceuticals in Q1 2022 and held it in 12 quarters.
- Group One Trading's scPharmaceuticals position peaked at $291K in Q3 2024.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.